Winstrol, Buy winstrol, Winstrol side effects
winstrolheader
Home      |        Services      |       Resources      |       Site Map      |       Contact Us
MENU
icon Winstrol
icon Winstrol side effects
icon Winstrol steroid
icon Oral winstrol
icon Winstrol for woman
icon Winstrol dosage
   
  Featured Links
 
icon Anabolic Steroids
icon Buy Steroids
icon Buy Steroids
icon Steroid Abuse
   
Winstrol dosage:
Alot of what holds true for the injectable version of this product (see: Winstrol Depot) also holds for the tabs. There are, however, two noticable differences between the two forms of administration. Nitrogen Retention is greater with use of the injectable version, when equal doses are administered. Paradoxically, it would seem that on a milligram for milligram basis, users have reported that oral administration of Stanozolol was more potent than the injectable produc for building muscle. This could be due to winstrol's ability to lower SHBG (Sex Hormone Binding Globulin) levels and also elevate IGF (Insulin-Like Growth Factor) above those experienced with the injectable version.

British Dragon winstrol tabs are one of the most popular versions on the market today. Women athletes commonly reported the use of Stanozolol at a dosage of 10mg daily, and I am of the opinion that women should preferentially use the injectable version when possible.
Men have found that it works well when used in 50-100mg daily doses, and stacked very efficiently with Testosterone and Nandrolone or Trenbolone.

Reported Characteristics:
Pharmaceutical Name:Stanozolol Chemical Name:17-beta-hydroxy-17-methyl-5alpha-androstano[3,2-c]pyrazole Cutting/Bulking:Cutting Anabolic Rating:320 Active-Life: About 8 hours Drug Class: Anabolic/Androgenic steroid (Oral) Average Reported Dosage: Males 25-50-mg daily Women 10mg daily Acne: Possible Water Retention: No High Blood Pressure: Rare Liver Toxic: High in high oral dosages DHT Conversion: DHT-derived Decreases HPTA Function: No Average Price:Up to $1/10mg tab

 
Research Findings Expected to Ease Treatment of Low Neutrophil Counts in Cancer Patients
Multicenter trial led by St. Jude Children's Research Hospital investigators may change neutropenia treatment for all childhood cancer patients MEMPHIS, Tenn., March 10 /PRNewswire-USNewswire/ -- For patients like 10-year-old Sabrina Jo Spence, new...




QLT Announces Phase II Clinical Trial Results and Development Plans for the Punctal Plug Delivery System
-- 90-Day Retention Rate of 81% for Latest Punctal Plug Prototype Device -- No Dose Response Seen with Higher Doses in Phase II Clinical Studies -- Expand Development Plans of the Punctal Plug Delivery System in Allergic Conjunctivitis --...




AM-Pharma presents positive results for Phase II trial in Acute Kidney Injury
AM-Pharma presents positive Phase II results for potential First-In-Class drug AM-Pharma presents positive results of its Phase II clinical trial with Alkaline Phosphatase in Acute Kidney Injury at the ISICEM conference in Brussels Alkaline...




Medicine to Lower Blood Pressure Significantly Decreases Risk For Cardiovascular Disease, Stroke
Study highlights: Medicine to lower blood pressure decreased risk of cardiovascular disease, including stroke, by more than 25 percent among normal weight, overweight and obese patients. Obese patients, who had higher initial blood pressure...




Acologix Presents Data on Cartilage Regeneration by AC-100 at the 56th Annual Meeting of the Orthopaedic Research Society
HAYWARD, Calif., March 6 /PRNewswire/ -- Acologix, Inc., a privately held biopharmaceutical company, today announced the results of its latest preclinical study demonstrating that AC-100, its therapeutic product candidate derived from an endogenous...




Genomic Health Announces Publication of Study Using Oncotype DX(R) in Node-Negative and Node-Positive Breast Cancer Patients Treated With Aromatase Inhibitors
REDWOOD CITY, Calif., March 8 /PRNewswire-FirstCall/ -- Genomic Health, Inc. (NASDAQ:GHDX) today announced the publication of positive results from a large international study which demonstrated that the Oncotype DX® breast cancer...




New Data Presented at American Burn Association's Annual Meeting Support Safety Profile of RECOTHROM Thrombin, Topical (Recombinant) in Pediatric Patients
SEATTLE--(BUSINESS WIRE)--Mar 9, 2010 - ZymoGenetics, Inc. (NASDAQ:ZGEN), today announced the presentation of safety and immunogenicity data among pediatric burn patients at the 42nd Annual Meeting of the American Burn Association in Boston, MA. The...




Mayo Researchers Link Obesity to Worse Outcome in Patients Being Treated for Colon Cancer
Researchers say that obesity leads to more aggressive colon cancer and that the risk differs between men and women ROCHESTER, Minn.--(BUSINESS WIRE)--Mar 9, 2010 - It's long been known that obesity is linked to increased risk of developing...




BioMimetic Therapeutics Presents Promising Pre-Clinical Sports Medicine Data at the 2010 ORS Meeting
Data Demonstrates rhPDGF-BB, in Combination with Tissue Specific Matrix Materials, Promotes Healing in Achilles and Rotator Cuff Tears   FRANKLIN, Tenn.--(BUSINESS WIRE)--Mar 9, 2010 - BioMimetic Therapeutics, Inc. (NASDAQ: BMTI) announced...




Inhibitex to Present at Two Upcoming Conferences
ATLANTA--(BUSINESS WIRE)--Mar 8, 2010 - Inhibitex, Inc. (Nasdaq: INHX), today announced that Russell H. Plumb, President and Chief Executive Officer, is scheduled to present an overview of the company and its pipeline of differentiated antiviral...




Warfarin Users Appear More Likely To Develop Brain Bleeding Following Stroke Treatment
CHICAGO, March 8, 2010-Patients already taking warfarin who develop an acute stroke appear more likely to experience a brain hemorrhage following treatment with an intravenous clot-dissolving medication, even if their blood clotting function...




INSYS Therapeutics, Inc. Announces Positive Phase III Efficacy Trial Results for Fentanyl Sublingual Spray
- Unique delivery method achieves statistical significance in five minutes         PHOENIX, March 09, 2010 /PRNewswire/ -- INSYS Therapeutics, Inc. announces positive results from the pivotal phase III efficacy trial for patients...




Nektar Announces Positive Prelim. Data for NKTR-102 in Ovarian Cancer
SAN CARLOS, Calif., March 8, 2010 -- Nektar Therapeutics (Nasdaq: NKTR) today announced preliminary progression-free survival data from the first stage of a two-stage Phase 2 clinical study evaluating single-agent treatment with NKTR-102 in women...




Omthera Pharmaceuticals, Inc. Closes a $6.5M Series A led by Sofinnova Partners to Advance Epanova, a Prescription Omega 3 Therapy
Dyslipidemia Experts Jerry Wisler and Michael Davidson, M.D. Co-Found New Pharmaceutical Company Developing a Prescription Omega 3 Treatment of High Triglycerides NEW YORK--(BUSINESS WIRE)--Mar 8, 2010 - Omthera Pharmaceuticals, Inc., an...




Nektar Announces Positive Phase 2 Clinical Data from First Stage of NKTR-102 Study in Women with Platinum-Resistant Ovarian Cancer
SAN CARLOS, Calif., March 8 /PRNewswire-FirstCall/ -- Nektar Therapeutics (NASDAQ:NKTR) today announced preliminary progression-free survival data from the first stage of a two-stage Phase 2 clinical study evaluating single-agent treatment...




Millennium Announces First Clinical Data For TAK-700 Prostate Molecule at ASCO GU
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Mar 8, 2010 - Millennium: The Takeda Oncology Company today announced the presentation of safety, pharmacokinetic and efficacy data from the Phase I portion of a Phase I/II clinical trial evaluating TAK-700 in...




Argos Therapeutics Presents Positive Phase 2 Data of its Arcelis Personalized Immunotherapy Platform in Metastatic RCC at ASCO GU Symposium
-Immunotherapy Demonstrates Encouraging Immune and Clinical Responses-   DURHAM, N.C.--(BUSINESS WIRE)--Mar 8, 2010 - Argos Therapeutics today announced the presentation of positive data from a Phase 2 trial that evaluated the safety,...




New Imiquimod Formulation for Actinic Keratosis published in JAAD
Study Examining New Short-Course Imiquimod Formulation in Actinic Keratosis published in Journal of the American Academy of Dermatology Imiquimod 3.75% Is Now Available In Pharmacies Across Canada TORONTO, ON, March 8, 2010 – The Journal of...




Recentin Did Not Meet Primary Endpoint in Horizon III Study in Metastatic Colorectal Cancer
LONDON, March 8, 2010-- AstraZeneca today announced the top-line results of a Phase II/III study evaluating RECENTIN (cediranib) compared with Avastin (bevacizumab) in patients with first-line metastatic colorectal cancer (mCRC).  This study,...




Genmab Announces Results from Zalutumumab Phase III Study of Refractory Head and Neck Cancer Patients
Copenhagen, Denmark; March 08, 2010 – Genmab A/S (OMX: GEN) announced today top-line results from a zalutumumab Phase III study in patients with recurrent or metastatic squamous cell carcinoma of the head and neck (SCCHN) who failed standard...




Scientists Find New Form of Prion Disease that Damages Brain Arteries
Study in Mice May Offer Clues for Treating Alzheimer's Disease WHAT: National Institutes of Health (NIH) scientists investigating how prion diseases destroy the brain have observed a new form of the disease in mice that does not cause the...




Poniard Pharmaceuticals Presents Positive Survival Data from a Phase 2 Clinical Study of Picoplatin in Metastatic Prostate Cancer at the 2010 American Society of Clinical Oncology Genitourinary Cancers Symposium
SOUTH SAN FRANCISCO, Calif., March 5 /PRNewswire-FirstCall/ -- Poniard Pharmaceuticals, Inc. (NASDAQ:PARD) , a biopharmaceutical company focused on innovative oncology therapies, today announced the presentation of positive final data, including...




Poniard Pharm Presents Positive Survival Data from a P2 Study in Metastatic Prostate Cancer
Poniard Pharmaceuticals Presents Positive Survival Data from a Phase 2 Clinical Study of Picoplatin in Metastatic Prostate Cancer at the 2010 American Society of Clinical Oncology Genitourinary Cancers Symposium SOUTH SAN FRANCISCO, Calif. –...




Common Osteoporosis Drugs Are Associated With a Decrease in Risk of Breast Cancer
SEATTLE, March 5 /PRNewswire/ -- Women who take some types of bone-building drugs used to prevent and treat osteoporosis may be at lower risk of breast cancer, according to a study by U.S. researchers published today in the British Journal of...




Researchers Report that Thymosin beta 4 Improves Neurological Function after Stroke
Tβ4 Found to Stimulate Oligoprogenitor Cells ROCKVILLE, Md.--(BUSINESS WIRE)--Mar 5, 2010 - REGENERX BIOPHARMACEUTICALS, INC. (NYSE Alternext US:RGN) announced that a research team from the Henry Ford Hospital in Detroit, MI reported that...




Experimental Vaccine Protects Monkeys Against Chikungunya
Mosquito-borne virus has infected millions of people in Asia, Africa and Europe GALVESTON, Texas — Imagine a mosquito-borne virus that has already infected millions of people in recent outbreaks in South and Southeast Asia, the islands of the...




Open-Label Study Supports Long-Term Efficacy Of Xenazine (Tetrabenazine) For HD Chorea
Results achieved over 80 weeks of treatment consistent with statistically significant reduction in chorea associated with Huntington's disease demonstrated in pivotal study DEERFIELD, Ill., March 5, 2010 – Lundbeck Inc. today announced the...




Phase III REGION-I Study Shows PEP005 (ingenol mebutate) Gel 0.05% May Reduce Pre-Cancerous Skin Lesions in Patients with Actinic Keratosis
Data Presented at the 68th Annual Meeting of the American Academy of Dermatology PARSIPPANY, N.J., March 5 /PRNewswire/ -- Specialty pharmaceutical company LEO Pharma today announced that findings from a Phase III study evaluating PEP005...




ADVANCE-2 Study Results Demonstrate Investigational Anticoagulant Apixaban Was Statistically Superior To Enoxaparin In The Prevention Of Venous Thromboembolism Following Knee Replacement Surgery
Phase III Data Published in The Lancet also Demonstrate Comparable Rates of Bleeding with Apixaban Versus Enoxaparin PRINCETON, N.J. & NEW YORK--(BUSINESS WIRE)--Mar 4, 2010 - Apixaban, an oral anticoagulant being developed by Bristol-Myers...




Presentations on Geron's Telomerase Inhibitor At AACR Special Conference
Data Shows Activity of Imetelstat Against Cancer Stem Cells MENLO PARK, Calif.--(BUSINESS WIRE)--Mar 2, 2010 - Geron Corporation (Nasdaq:GERN) today announced several presentations at the American Association for Cancer Research (AACR)...




Beta Blocker Therapy Underused in Heart Failure Patients
New Saint Louis U research suggests reliance on technology rather than drug therapy ST. LOUIS, March 4, 2010 – New Saint Louis University research has found that beta blockers, a class of drugs used to prevent the progression of heart failure...




Argos Therapeutics Publishes Positive Immune Response, Safety and Manufacturing Data for its Arcelis? HIV Program in Clinical Immunology
DURHAM, N.C.--(BUSINESS WIRE)--Mar 4, 2010 - Argos Therapeutics today announced the publication of a manuscript in the February edition of Clinical Immunology, detailing positive immune response, safety and manufacturing data for its...




Negative Phase III Trial Results for Latrepirdine (Dimebon)
Alzheimer's Association Statement CHICAGO, March 3 /PRNewswire-USNewswire/ -- "The Alzheimer's Association is disappointed to learn of the negative results from the Phase III clinical trial of latrepirdine (Dimebon)," said William Thies, Ph.D.,...




Stelara and Remicade Data in Treatment of Plaque Psoriasis to be Presented at American Academy of Dermatology (AAD) Meeting
MIAMI, March 4 /PRNewswire/ -- Data evaluating the efficacy and safety of STELARA(TM) (ustekinumab) and REMICADE® (infliximab) in patients with plaque psoriasis who had an inadequate response to Enbrel® (etanercept) will be presented at the...




Dendreon Presents Updated IMPACT Results Confirming Provenge Improves Overall Survival in Patients With Metastatic Castrate-Resistant Prostate Cancer
-- Data to be Presented at ASCO-GU Annual Symposium -- SEATTLE, March 3 /PRNewswire-FirstCall/ -- Dendreon Corporation (NASDAQ: DNDN) today announced updated results from its pivotal Phase 3 IMPACT (IMmunotherapy for Prostate AdenoCarcinoma...




Raptor Pharmaceutical Announces Publication of Data Supporting Potential Efficacy of WntTide(TM) in Treatment of Triple-Negative Breast Cancer
NOVATO, Calif., Mar 4, 2010 (GlobeNewswire via COMTEX) -- Raptor Pharmaceutical Corp. ("Raptor" or the "Company") (Nasdaq:RPTP) today announced the publication of data on a proprietary, Mesd (Mesoderm development)-based peptide, also known as...




Cabazitaxel Increased Survival for Patients with Advanced Hormone-Refractory Prostate Cancer
- Results observed in patients treated with cabazitaxel plus prednisone whose disease progressed despite prior docetaxel-based chemotherapy - - Data from large international Phase 3 study to be presented at the 2010 Genitourinary Cancers...




Anavex comments on failure of Pfizer and Medivation's Alzheimer's investigational drug Dimebon during Phase 3 clinical trials
GENEVA, SWITZERLAND, March 3 /PRNewswire-FirstCall/ -- Anavex Life Sciences Corp. ("ANAVEX") (OTCBB: AVXL) today issued a statement following today's announcement from Pfizer and Medivation (NASDAQ:MDVN) that their investigational Alzheimer's...




Patient age not a factor in use of second-line therapy for lung cancer
'Salvage' therapy just as suitable for NSCLC patients over age 70 as for younger patients Research published in the March issue of the Journal of Thoracic Oncology sought to determine whether differences existed in tolerance and efficacy between...




HIV Vaccine Strategy Expands Immune Responses
Mosaic vaccines show promise in reducing the spread of deadly virus LOS ALAMOS, New Mexico, March 3, 2010—Two teams of researchers—including Los Alamos National Laboratory theoretical biologists Bette Korber, Will Fischer, Sydeaka...




Home    |    Services   |    Resources    |    Site Map   |    Contact Us
Copy rights reserved by iwinstrol.com